Dr. Gandara on the Utility of TMB in NSCLC
David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.
David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.
Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.
Neli Ulrich, PhD, MS, of Huntsman Cancer Institute, has been awarded the 2024 Governor’s Medal for Science and Technology.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.
This event is supported by Pfizer, Exelixis and Regeneron…
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.